Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Harvard Bioscience, Inc. (HBIO) had Consolidated Net Income/Loss of $-2.91M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$22.73M |
|
$-2.91M |
|
$10.10M |
|
$12.63M |
|
$23.70M |
|
$-0.98M |
|
$-1.92M |
|
$-2.90M |
|
$-2.90M |
|
$-2.91M |
|
$-2.91M |
|
|
Consolidated Net Income/Loss |
$-2.91M |
$-2.91M |
|
$-0.98M |
|
$0.89M |
|
4.53M |
|
4.53M |
|
$-0.64 |
|
$-0.64 |
|
| Balance Sheet Financials | |
$46.46M |
|
$5.35M |
|
$29.82M |
|
$76.29M |
|
$24.79M |
|
$36.68M |
|
$44.08M |
|
$68.87M |
|
$7.42M |
|
$-8.13M |
|
$7.42M |
|
4.55M |
|
| Cash Flow Statement Financials | |
$-0.34M |
|
$-1.54M |
|
$-0.05M |
|
$8.61M |
|
$6.50M |
|
$-2.11M |
|
$0.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.87 |
|
-- |
|
-- |
|
0.83 |
|
4.95 |
|
55.57% |
|
-4.30% |
|
-4.30% |
|
-- |
|
-12.74% |
|
-12.80% |
|
$-1.45M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
0.45 |
|
1.57 |
|
57.42 |
|
-39.23% |
|
35.78% |
|
-3.81% |
|
-6.60% |
|
$1.63 |
|
$-0.32 |
|
$-0.07 |
|